ArticleJournal of gastrointestinal oncology2025
Safety and efficacy of transcatheter chemoembolization combined with hepatic arterial infusion chemotherapy for unresectable primary liver cancer: a single-center prospective study.
Article in Journal of gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Primary liver cancer (PLC) is a leading cause of cancer-related mortality, with many patients ineligible for curative resection. Transcatheter arterial chemoembolization (TACE) and hepatic arterial infusion chemotherapy (HAIC) are two key interventional therapies recommended for unresectable cases. Recent studies suggest that combining them may enhance treatment efficacy compared to either approach alone. This prospective study aims to evaluate the safety and efficacy of TACE combined with HAIC in patients with unresectable PLC. Methods: Patients with unresectable primary hepatocellular carcinoma (China Liver Cancer stage IIa-III, without distant metastasis) who received TACE combined with HAIC from February 2023 to September 2024, at the Department of Interventional Treatment, Beijing No. 6 Hospital, were included. The primary endpoint was overall survival (OS) and progression-free survival (PFS). Safety was evaluated in all patients who received at least one treatment cycle. Tumor response was assessed using the modified Response Evaluation Criteria in Solid Tumors (mRECIST). Results: Among the 29 eligible patients, the median follow-up month was 16 months. The mRECIST assessments were available for 22 patients. Among them, six (27.3%) achieved complete response, 11 (50.0%) showed partial response, two (9.1%) showed progressive disease, and three (13.64%) showed stable disease. The objective response rate was 77.3%, and the disease control rate was 90.9%. Three patients (10.3%) underwent successful surgical resection following treatment. Median OS and PFS were not reached. The estimated 6-, 12-, and 18-month OS rates were 90%, 85% and 85%, respectively. No grade 3-5 treatment-related adverse events were observed. Conclusions: In patients with China Liver Cancer stage IIa-III, the combined treatment demonstrated a favorable safety profile and preliminary efficacy, also enabling transformative resection in some patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.